Analysts expect Cardiome Pharma Corp (TSE:COM) to report $-0.20 EPS on May, 12.They anticipate $0.12 EPS change or 150.00% from last quarter’s $-0.08 EPS. After having $-0.24 EPS previously, Cardiome Pharma Corp’s analysts see -16.67% EPS growth. The stock increased 3.41% or $0.14 on April 13, reaching $4.25. About shares traded. Cardiome Pharma Corp (TSE:COM) has risen 5.72% since September 8, 2016 and is uptrending. It has underperformed by 1.05% the S&P500.
Birks Group Class A Voting Shares (NYSEMKT:BGI) had a decrease of 6.77% in short interest. BGI’s SI was 190,000 shares in April as released by FINRA. Its down 6.77% from 203,800 shares previously. With 36,700 avg volume, 5 days are for Birks Group Class A Voting Shares (NYSEMKT:BGI)’s short sellers to cover BGI’s short positions. The SI to Birks Group Class A Voting Shares’s float is 7.25%. The stock increased 9.22% or $0.13 on April 13, reaching $1.54. About 36,582 shares traded or 25.88% up from the average. Birks Group Inc (NYSEMKT:BGI) has declined 19.69% since September 8, 2016 and is downtrending. It has underperformed by 26.46% the S&P500.
Cardiome Pharma Corp. is a specialty pharmaceutical company. The company has market cap of $133.48 million. The Firm is engaged in the development and commercialization of cardiovascular therapies for heart disease. It currently has negative earnings. The Company’s divisions are Europe and Rest of World.
Birks Group Inc is a Canada-based company engaged in designing, developing, making and retail of jewelry, timepieces and gifts. The company has market cap of $30.41 million. The Firm operates through two divisions: Retail and Other. It has a 10.57 P/E ratio. The Company’s Retail segment consists of all its retail activities in the United States and Canada on a combined basis.
